SG11201507447PA - Chimeric cytokine formulations for ocular delivery - Google Patents
Chimeric cytokine formulations for ocular deliveryInfo
- Publication number
- SG11201507447PA SG11201507447PA SG11201507447PA SG11201507447PA SG11201507447PA SG 11201507447P A SG11201507447P A SG 11201507447PA SG 11201507447P A SG11201507447P A SG 11201507447PA SG 11201507447P A SG11201507447P A SG 11201507447PA SG 11201507447P A SG11201507447P A SG 11201507447PA
- Authority
- SG
- Singapore
- Prior art keywords
- ocular delivery
- chimeric cytokine
- cytokine formulations
- formulations
- chimeric
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/545—IL-1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361779974P | 2013-03-13 | 2013-03-13 | |
| PCT/US2014/026416 WO2014160371A1 (en) | 2013-03-13 | 2014-03-13 | Chimeric cytokine formulations for ocular delivery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201507447PA true SG11201507447PA (en) | 2015-10-29 |
Family
ID=50680140
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201507447PA SG11201507447PA (en) | 2013-03-13 | 2014-03-13 | Chimeric cytokine formulations for ocular delivery |
| SG10201707477SA SG10201707477SA (en) | 2013-03-13 | 2014-03-13 | Chimeric cytokine formulations for ocular delivery |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201707477SA SG10201707477SA (en) | 2013-03-13 | 2014-03-13 | Chimeric cytokine formulations for ocular delivery |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20140308239A1 (es) |
| EP (1) | EP2968468B1 (es) |
| JP (1) | JP6450364B2 (es) |
| KR (1) | KR102236926B1 (es) |
| CN (2) | CN107693781B (es) |
| AU (2) | AU2014243839B2 (es) |
| BR (1) | BR112015022587A2 (es) |
| CA (1) | CA2903706C (es) |
| DK (1) | DK2968468T3 (es) |
| ES (1) | ES2884813T3 (es) |
| HK (1) | HK1246692A1 (es) |
| IL (1) | IL241171A0 (es) |
| MX (1) | MX2015012404A (es) |
| PL (1) | PL2968468T3 (es) |
| RU (1) | RU2015143521A (es) |
| SG (2) | SG11201507447PA (es) |
| WO (1) | WO2014160371A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG187231A1 (en) | 2010-07-29 | 2013-02-28 | Eleven Biotherapeutics Inc | Chimeric il-1 receptor type i agonists and antagonists |
| RU2015143521A (ru) | 2013-03-13 | 2017-04-19 | Илэвэн Байотерапьютикс, Инк. | Лекарственные формы химерных цитокинов для глазной доставки |
| WO2015138844A1 (en) | 2014-03-13 | 2015-09-17 | Eleven Biotherapeutics, Inc. | Methods for production of stable chimeric cytokine protein formulations in blow fill seal containers |
| ES2584534B1 (es) * | 2015-03-27 | 2017-03-13 | Retinset, S.L. | Formulación tópica oftálmica de bosentan |
| US11324807B2 (en) | 2015-04-28 | 2022-05-10 | Swedish Orphan Biovitrum Ab (Publ) | Compositions comprising anakinra |
| US20190076466A1 (en) * | 2015-07-07 | 2019-03-14 | Liferaft Biosciences | Reduced sodium poloxamer-188 formulations and methods for use |
| TW202335664A (zh) * | 2015-11-30 | 2023-09-16 | 日商樂敦製藥股份有限公司 | 眼科組成物 |
| EP4241759A1 (en) * | 2016-10-12 | 2023-09-13 | PS Therapy, Inc. | Artificial tear, contact lens and drug vehicle compositions and methods of use thereof |
| WO2018142514A1 (ja) * | 2017-02-01 | 2018-08-09 | 協和発酵キリン株式会社 | ダルベポエチンを含む液体医薬組成物 |
| WO2021237091A1 (en) * | 2020-05-21 | 2021-11-25 | Coherus Biosciences, Inc. | Systems and methods for producing sterile injection devices |
| KR20240004576A (ko) * | 2021-04-22 | 2024-01-11 | 온스파이라 테라퓨틱스, 인크. | 인터류킨-1 수용체 길항제의 조성물 |
| WO2023169686A1 (en) | 2022-03-10 | 2023-09-14 | Buzzard Pharmaceuticals AB | Inhibitor of interleukin-1 receptor type 1 for use in the treatment of cancer |
Family Cites Families (132)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL188266C (nl) | 1975-07-29 | 1992-05-18 | Merck & Co Inc | Werkwijze ter bereiding van een oogheelkundig inplantaat. |
| ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
| US5693489A (en) | 1984-03-30 | 1997-12-02 | Associated Universities, Inc. | Cloning and expression of the gene for bacteriophage T7 RNA polymerase |
| US5998578A (en) | 1984-05-18 | 1999-12-07 | New England Medical Center Hospitals, Inc. | Biologically active fragments of IL-1β |
| EP0569687B1 (en) | 1984-05-18 | 2002-08-21 | New England Medical Center Hospitals, Inc. | Human IL-1 cDNA sequences encoding biologically-active human IL-1 proteins |
| US5484887A (en) | 1984-06-19 | 1996-01-16 | Immunex Corporation | Homogeneous interleukin 1 |
| DK172052B1 (da) | 1984-12-21 | 1997-09-29 | Otsuka Pharma Co Ltd | Antitumor-aktivt stof, fremgangsmåde til dets fremstilling, lægemiddel indeholdende stoffet, gen kodende for stoffet, vektor indeholdende genet samt rekombinant mikroorganisme transformet med en sådan vektor |
| US6107465A (en) | 1984-12-21 | 2000-08-22 | Otsuka Pharmaceutical Co., Ltd. | IL-1β and derivatives thereof and drugs |
| US5122459A (en) | 1984-12-31 | 1992-06-16 | Immunex Corporation | Gene encoding biologically active human interleukin 1 |
| US4770781A (en) | 1986-03-03 | 1988-09-13 | Merck & Co., Inc. | Purification of human interleukin-1 species |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4883658A (en) | 1986-04-28 | 1989-11-28 | Holly Frank J | Ophthalmic solution for treatment of dry-eye syndrome |
| US4804539A (en) | 1986-07-28 | 1989-02-14 | Liposome Technology, Inc. | Ophthalmic liposomes |
| US5278151A (en) | 1987-04-02 | 1994-01-11 | Ocular Research Of Boston, Inc. | Dry eye treatment solution |
| KR0148009B1 (ko) | 1988-05-27 | 1998-08-01 | 그래고리 비. 아보트 | 인터루킨-1 억제제 |
| US6159460A (en) | 1988-05-27 | 2000-12-12 | Amgen Inc. | Method for treating interleukin-1 mediated diseases |
| US6858409B1 (en) | 1988-05-27 | 2005-02-22 | Amgen Inc. | Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors |
| US5075222A (en) | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
| AU4005289A (en) | 1988-08-25 | 1990-03-01 | Smithkline Beecham Corporation | Recombinant saccharomyces |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| DE69032251T2 (de) | 1989-02-27 | 1998-08-13 | Massachusetts Institute Of Technology, Cambridge, Mass. | Il-1, dessen biologische aktivität inhibiert ist |
| US5075104A (en) | 1989-03-31 | 1991-12-24 | Alcon Laboratories, Inc. | Ophthalmic carboxy vinyl polymer gel for dry eye syndrome |
| CA2068320C (en) | 1989-11-29 | 2000-10-17 | Robert Hageman | Production of recombinant human interleukin-1 inhibitor |
| WO1991017184A1 (en) | 1990-04-27 | 1991-11-14 | The Upjohn Company | Modified interleukin-1 inhibitors |
| ZA912797B (en) | 1990-05-29 | 1992-12-30 | Boston Ocular Res | Dry eye treatment process and solution |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| WO1992013885A1 (en) | 1991-02-05 | 1992-08-20 | University Of Maryland | MODIFIED INTERLEUKIN-1$g(b) |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| WO1993007863A1 (en) | 1991-10-15 | 1993-04-29 | Mullarkey Michael F | Methods and compositions for treating allergic reactions |
| CA2122596C (en) | 1991-10-31 | 2008-06-03 | Nancy Jane Rothwell | Treatment of neurological conditions by an interleukin-1 inhibiting compound |
| PL175705B1 (pl) | 1992-09-17 | 1999-01-29 | Synergen Inc | Kompozycja farmaceutyczna |
| JPH08507680A (ja) | 1993-01-12 | 1996-08-20 | バイオジェン インコーポレイテッド | 組換え抗ｖｌａ４抗体分子 |
| US5340572A (en) | 1993-02-08 | 1994-08-23 | Insite Vision Incorporated | Alkaline ophthalmic suspensions |
| AU8016094A (en) | 1993-10-12 | 1995-05-04 | Mary Lake Polan | Method of contraception |
| US5861476A (en) | 1994-02-02 | 1999-01-19 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-1 receptor |
| IT1269989B (it) | 1994-09-21 | 1997-04-16 | Dompe Spa | Antagonisti recettoriali di il-1 ad aumentata attivita' inibitoria |
| JP3269770B2 (ja) | 1995-03-02 | 2002-04-02 | 参天製薬株式会社 | 再分散性の優れたイオン性高分子配合水性懸濁点眼剤 |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6096728A (en) | 1996-02-09 | 2000-08-01 | Amgen Inc. | Composition and method for treating inflammatory diseases |
| US6416753B1 (en) | 1996-03-15 | 2002-07-09 | The General Hospital Corporation | Method for modulating apoptosis |
| US6974682B1 (en) | 1996-08-26 | 2005-12-13 | Human Genome Sciences, Inc. | Soluble interleukin-1 receptor accessory molecule |
| WO1998022130A1 (en) | 1996-11-19 | 1998-05-28 | The Schepens Eye Research Institute, Inc. | Local use of il-1ra in corneal transplant rejection or disorders of the eye |
| EP2305027B1 (en) | 1996-12-03 | 2014-07-02 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
| CA2273852C (en) | 1996-12-06 | 2009-09-29 | Amgen Inc. | Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases |
| EP0977779A1 (en) | 1997-04-21 | 2000-02-09 | Schering Corporation | Mammalian cytokines; related reagents and methods |
| UA72189C2 (uk) | 1997-11-17 | 2005-02-15 | Янссен Фармацевтика Н.В. | Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот |
| US6337072B1 (en) | 1998-04-03 | 2002-01-08 | Hyseq, Inc. | Interleukin-1 receptor antagonist and recombinant production thereof |
| US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| US7906481B2 (en) | 1998-09-25 | 2011-03-15 | Sciaticon Ab | Specific TNF-A inhibitors for treating spinal disorders mediated by nucleous pulposus |
| KR101155191B1 (ko) | 1999-01-15 | 2012-06-13 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| US6471961B1 (en) | 1999-02-24 | 2002-10-29 | Edward L. Tobinick | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders |
| US6419944B2 (en) | 1999-02-24 | 2002-07-16 | Edward L. Tobinick | Cytokine antagonists for the treatment of localized disorders |
| JP3363832B2 (ja) | 1999-05-13 | 2003-01-08 | アルプス電気株式会社 | 薄膜構造体およびその製造方法 |
| MXPA02005731A (es) | 1999-12-10 | 2003-10-14 | Amgen Inc | Moleculas similares al antagonista del receptor de interleucina-1 y usos de las mismas. |
| CA2393532A1 (en) | 1999-12-10 | 2001-06-14 | Frank J. Calzone | Interleukin-1 receptor antagonist-like molecules and uses thereof |
| CA2395417A1 (en) | 1999-12-10 | 2001-06-14 | Amgen Inc. | Interleukin-1 receptor antagonist-related molecules and uses thereof |
| US20030007971A1 (en) | 2000-01-31 | 2003-01-09 | Hideaki Hara | Remedies for ophthalmic diseases |
| WO2001057082A2 (en) | 2000-02-03 | 2001-08-09 | Regeneration Technologies, Inc. | Extraction of growth factors from tissue |
| US20040028872A1 (en) | 2000-04-17 | 2004-02-12 | Edwards Mark Stephen | Method and apparatus for making bristle subassemblies |
| US6623736B2 (en) | 2000-05-02 | 2003-09-23 | Edward L. Tobinick | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders |
| WO2001087328A2 (en) | 2000-05-12 | 2001-11-22 | Immunex Corporation | Interleukin-1 inhibitors in the treatment of diseases |
| US20030026806A1 (en) | 2000-10-27 | 2003-02-06 | Amgen Inc. | Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof |
| US7087224B2 (en) | 2000-10-31 | 2006-08-08 | Amgen Inc. | Method of treating anemia by administering IL-1ra |
| US20030166069A1 (en) | 2000-11-28 | 2003-09-04 | Amgen, Inc. | Interleukin-1 receptor antagonist-like molecules and uses thereof |
| US7083784B2 (en) | 2000-12-12 | 2006-08-01 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| RU2003125640A (ru) | 2001-02-06 | 2005-03-10 | Мерк Патент ГмбХ (DE) | Модифицированный антагонист рецептора интерлейкина 1 (1l-1ra) с уменьшенной иммуногенностью |
| US20050143333A1 (en) | 2001-05-18 | 2005-06-30 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA) |
| US20030104996A1 (en) * | 2001-08-30 | 2003-06-05 | Tiansheng Li | L-methionine as a stabilizer for NESP/EPO in HSA-free formulations |
| US20030083301A1 (en) | 2001-09-06 | 2003-05-01 | Board Of Regents, The University Of Texas System | Therapeutic treatments for spinal cord injury via blockade of interleukin-1 receptor |
| FR2833268B1 (fr) * | 2001-12-12 | 2005-07-08 | Fabre Pierre Dermo Cosmetique | Nouvelle association contenant un poloxamer et de l'acide chondroitine sulfurique et/ou une glycoproteine et son utilisation |
| WO2003068920A2 (en) | 2002-02-13 | 2003-08-21 | Ludwig Institute For Cancer Research | Humanized gm-csf antibodies |
| US6890654B2 (en) | 2002-04-18 | 2005-05-10 | Northwestern University | Encapsulation of nanotubes via self-assembled nanostructures |
| US7029712B1 (en) | 2002-07-17 | 2006-04-18 | Biosyntrx Inc | Treatment for dry eye syndrome |
| WO2004060911A2 (en) | 2002-12-30 | 2004-07-22 | Amgen Inc. | Combination therapy with co-stimulatory factors |
| US20050033694A1 (en) | 2003-06-03 | 2005-02-10 | United States Postal Service. | System and method for fleet card management |
| ES2385888T3 (es) * | 2003-06-10 | 2012-08-02 | Lg Life Sciences Ltd. | Solución acuosa estable de eritropoyetina humana que no contiene albúmina sérica |
| US7261882B2 (en) | 2003-06-23 | 2007-08-28 | Reagents Of The University Of Colorado | Methods for treating neuropathic pain by administering IL-10 polypeptides |
| US20050023872A1 (en) | 2003-07-28 | 2005-02-03 | Hetzel Thomas R. | Modular seat cushion with interlocking human support and base portions and method of creating and using a seat cushion |
| CN1898266B (zh) | 2003-10-27 | 2011-09-21 | 惠氏公司 | 使用羟磷灰石层析除去高分子量聚集体 |
| KR100543466B1 (ko) | 2003-11-13 | 2006-01-20 | 삼성전자주식회사 | 영상 보간 장치 및 방법 |
| JP4845741B2 (ja) * | 2003-12-23 | 2011-12-28 | ファルマシア コーポレーション | 安定な成長ホルモン液体製剤 |
| US7674464B2 (en) | 2004-03-04 | 2010-03-09 | The University Of Tennessee Research Foundation | Intracellular interleukin-1 receptor antagonists |
| US7482323B2 (en) | 2004-03-04 | 2009-01-27 | The University Of Tennessee Research Foundation | Intracellular interleukin-1 receptor antagonist and uses thereof |
| AU2005231822B2 (en) | 2004-04-02 | 2011-07-21 | Swedish Orphan Biovitrum Ab (Publ) | Methods of reducing aggregation of IL-1ra |
| US8618054B2 (en) | 2004-05-05 | 2013-12-31 | Valorisation-Rechereche Société en Commandite | Interleukin-1 receptor antagonists, compositions, and methods of treatment |
| EP1750746A1 (en) | 2004-06-04 | 2007-02-14 | Regeneron Pharmaceuticals, Inc. | Methods of using il-1 antagonists to treat autoinflammatory disease |
| DK1778723T3 (da) | 2004-08-17 | 2012-12-03 | Regeneron Pharma | Il-1-antagonistformuleringer |
| WO2005021578A2 (en) | 2004-08-25 | 2005-03-10 | Amprotein Corporation | A novel chimeric polypeptide and use thereof |
| RU2007123604A (ru) | 2004-11-24 | 2008-12-27 | Тэракайн Корпорэйшн (Us)Тэракайн Корпорэйшн (Us) | Имплантат для внутриглазной доставки лекарственных средств |
| JP2008521426A (ja) | 2004-12-02 | 2008-06-26 | ドマンティス リミテッド | ドメイン抗体への複合体化により血清半減期が延長されたｐｌａｄドメインペプチド |
| EP2377554A1 (en) | 2005-07-22 | 2011-10-19 | Amgen, Inc | Concentrated protein lyophilates, methods and uses |
| EP2116258A1 (en) | 2005-09-01 | 2009-11-11 | Schering Corporation | Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease |
| IL172297A (en) | 2005-10-03 | 2016-03-31 | Compugen Ltd | Soluble vegfr-1 variants for the diagnosis of preeclampsia |
| CA2624648A1 (en) | 2005-10-21 | 2007-04-26 | Amgen Inc. | Methods of decreasing vascular calcification using il-1 inhibitors |
| KR20110079922A (ko) | 2006-04-14 | 2011-07-11 | 노파르티스 아게 | 안과 장애 치료를 위한 ｉｌ－1 항체의 용도 |
| EP2008100A4 (en) | 2006-04-18 | 2009-12-16 | Univ Leland Stanford Junior | ESTABLISHING ANTIBODY PROFILES FOR DETERMINING PATIENT SENSITIVITY TO TREATMENT |
| WO2007145618A1 (en) | 2006-06-12 | 2007-12-21 | Therakine Limited | Topical treatment for diseases of eye surface |
| US20080095754A1 (en) | 2006-10-18 | 2008-04-24 | Burke Susan E | Ophthalmic compositions comprising diglycine |
| US8399421B2 (en) | 2007-03-30 | 2013-03-19 | The Board Of Regents Of The University Of Texas System | Treatment for neuropathic pain due to spinal cord injury |
| GB0708376D0 (en) | 2007-05-01 | 2007-06-06 | Alligator Bioscience Ab | Novel polypeptides and uses thereof |
| CN104873972A (zh) | 2007-05-29 | 2015-09-02 | 诺华股份有限公司 | 抗IL-1β治疗的新适应症 |
| WO2008155134A1 (en) | 2007-06-21 | 2008-12-24 | Technische Universität München | Biological active proteins having increased in vivo and/or vitro stability |
| KR101430584B1 (ko) | 2007-07-05 | 2014-08-14 | 삼성전자주식회사 | 이동 통신 시스템에서 심 어플리케이션 툴킷을 제공하는장치 및 방법 |
| MX2010001684A (es) | 2007-08-15 | 2010-04-21 | Amunix Inc | Composiciones y metodos para modificar propiedades de polipeptidos biologicamente activos. |
| US10105441B2 (en) | 2007-08-16 | 2018-10-23 | The Schepens Eye Research Institute, Inc. | Method for inhibiting or reducing dry eye disease by IL-1Ra |
| WO2009048961A1 (en) | 2007-10-08 | 2009-04-16 | Anaphore, Inc. | Trimeric il-1ra |
| ES2387236T3 (es) * | 2007-12-20 | 2012-09-18 | Merck Serono S.A. | Formulaciones de interferón beta pegilado |
| JP5886523B2 (ja) | 2008-01-09 | 2016-03-16 | ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド | 眼の炎症性障害を処置するための治療組成物 |
| KR20100120289A (ko) * | 2008-01-15 | 2010-11-15 | 애보트 게엠베하 운트 콤파니 카게 | 분말상 단백질 조성물 및 이의 제조 방법 |
| WO2010089522A1 (en) | 2009-07-16 | 2010-08-12 | Arecor Limited | Stable formulation of a therapeutic protein |
| CN102209554A (zh) * | 2008-09-10 | 2011-10-05 | 弗·哈夫曼-拉罗切有限公司 | 用于防止蛋白质氧化降解的组合物和方法 |
| US8298533B2 (en) | 2008-11-07 | 2012-10-30 | Medimmune Limited | Antibodies to IL-1R1 |
| KR20110096553A (ko) | 2008-11-28 | 2011-08-30 | 아보트 러보러터리즈 | 안정한 항체 조성물 및 이의 안정화 방법 |
| US20120014970A1 (en) | 2009-01-09 | 2012-01-19 | Reza Dana | Therapeutic Compositions for Treatment of Corneal Disorders |
| EP2385839B1 (en) | 2009-01-09 | 2014-11-26 | The Schepens Eye Research Institute, Inc. | Therapeutic compositions for treatment of corneal disorders |
| WO2010096558A1 (en) | 2009-02-18 | 2010-08-26 | Eyeon Particle Sciences Llc | Bi-functional co-polymer use for ophthalmic and other topical and local applications |
| EP2248518B1 (en) | 2009-04-17 | 2013-01-16 | Merz Pharma GmbH & Co. KGaA | Formulation for stabilizing proteins, peptides or mixtures thereof. |
| WO2011011797A2 (en) | 2009-07-24 | 2011-01-27 | The Board Of Trustees Of The Leland Stanford Junior University | Cytokine compositions and methods of use thereof |
| WO2011028344A2 (en) | 2009-08-25 | 2011-03-10 | Amunix Operating Inc. | Interleukin-1 receptor antagonist compositions and methods of making and using same |
| AU2010303166A1 (en) | 2009-10-10 | 2012-05-24 | Eleven Biotherapeutics, Inc. | IL-17 family cytokine compositions and uses |
| WO2011063195A2 (en) | 2009-11-20 | 2011-05-26 | Dr. Reddy's Laboratories Ltd. | Purification of modified cytokines |
| US9011861B2 (en) | 2010-02-25 | 2015-04-21 | Schepens Eye Research Institute | Therapeutic compositions for the treatment of dry eye disease |
| EP4450523A2 (en) | 2010-04-02 | 2024-10-23 | Amunix Pharmaceuticals, Inc. | Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same |
| US20130195868A1 (en) | 2010-06-24 | 2013-08-01 | Eleven Biotherapeutics, Inc. | Treating surface of the eye disorders |
| SG187231A1 (en) | 2010-07-29 | 2013-02-28 | Eleven Biotherapeutics Inc | Chimeric il-1 receptor type i agonists and antagonists |
| CN103249429A (zh) * | 2010-11-08 | 2013-08-14 | 希尔洛有限公司 | 缓冲的眼用组合物以及使用其的方法 |
| WO2012103240A2 (en) | 2011-01-25 | 2012-08-02 | Eleven Biotherapeutics, Inc. | Receptor binding agents |
| EP2686431B1 (en) | 2011-03-14 | 2016-08-03 | Phlogo ApS | Antagonists of the interleukin- 1 receptor |
| JP2014522868A (ja) * | 2011-07-29 | 2014-09-08 | イレブン・バイオセラピユーテイクス・インコーポレイテツド | 精製タンパク質 |
| RU2015143521A (ru) | 2013-03-13 | 2017-04-19 | Илэвэн Байотерапьютикс, Инк. | Лекарственные формы химерных цитокинов для глазной доставки |
-
2014
- 2014-03-13 RU RU2015143521A patent/RU2015143521A/ru not_active Application Discontinuation
- 2014-03-13 ES ES14722435T patent/ES2884813T3/es active Active
- 2014-03-13 AU AU2014243839A patent/AU2014243839B2/en active Active
- 2014-03-13 SG SG11201507447PA patent/SG11201507447PA/en unknown
- 2014-03-13 JP JP2016502126A patent/JP6450364B2/ja active Active
- 2014-03-13 SG SG10201707477SA patent/SG10201707477SA/en unknown
- 2014-03-13 CN CN201710970359.5A patent/CN107693781B/zh active Active
- 2014-03-13 CN CN201480025086.1A patent/CN105392494A/zh active Pending
- 2014-03-13 WO PCT/US2014/026416 patent/WO2014160371A1/en active Application Filing
- 2014-03-13 US US14/209,605 patent/US20140308239A1/en not_active Abandoned
- 2014-03-13 PL PL14722435T patent/PL2968468T3/pl unknown
- 2014-03-13 KR KR1020157028630A patent/KR102236926B1/ko active IP Right Grant
- 2014-03-13 CA CA2903706A patent/CA2903706C/en active Active
- 2014-03-13 MX MX2015012404A patent/MX2015012404A/es unknown
- 2014-03-13 EP EP14722435.6A patent/EP2968468B1/en active Active
- 2014-03-13 BR BR112015022587A patent/BR112015022587A2/pt not_active IP Right Cessation
- 2014-03-13 DK DK14722435.6T patent/DK2968468T3/da active
-
2015
- 2015-09-03 IL IL241171A patent/IL241171A0/en unknown
-
2017
- 2017-08-07 US US15/670,840 patent/US10799589B2/en active Active
-
2018
- 2018-05-18 HK HK18106479.7A patent/HK1246692A1/zh unknown
- 2018-12-18 AU AU2018282269A patent/AU2018282269B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2884813T3 (es) | 2021-12-13 |
| CN107693781A (zh) | 2018-02-16 |
| KR20150126688A (ko) | 2015-11-12 |
| RU2015143521A (ru) | 2017-04-19 |
| EP2968468A1 (en) | 2016-01-20 |
| CN107693781B (zh) | 2021-11-09 |
| JP2016521252A (ja) | 2016-07-21 |
| AU2014243839A1 (en) | 2015-09-17 |
| IL241171A0 (en) | 2015-11-30 |
| KR102236926B1 (ko) | 2021-04-06 |
| JP6450364B2 (ja) | 2019-01-09 |
| PL2968468T3 (pl) | 2021-12-20 |
| US20180177877A1 (en) | 2018-06-28 |
| AU2018282269B2 (en) | 2020-06-11 |
| CN105392494A (zh) | 2016-03-09 |
| BR112015022587A2 (pt) | 2017-10-24 |
| AU2018282269A1 (en) | 2019-01-17 |
| HK1246692A1 (zh) | 2018-09-14 |
| CA2903706C (en) | 2024-01-23 |
| CA2903706A1 (en) | 2014-10-02 |
| WO2014160371A1 (en) | 2014-10-02 |
| EP2968468B1 (en) | 2021-07-14 |
| US10799589B2 (en) | 2020-10-13 |
| DK2968468T3 (en) | 2021-07-26 |
| RU2015143521A3 (es) | 2018-03-22 |
| US20140308239A1 (en) | 2014-10-16 |
| SG10201707477SA (en) | 2017-10-30 |
| MX2015012404A (es) | 2016-02-03 |
| AU2014243839B2 (en) | 2019-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1246692A1 (zh) | 用於眼部遞送的嵌合細胞因子製劑 | |
| IL246025A0 (en) | Formulations for neoplasia compounds | |
| EP3065716C0 (en) | FORMULATIONS | |
| HK1220617A1 (zh) | 因子 多肽調配物 | |
| EP2970924A4 (en) | PHYTASEFORMULIERUNG | |
| GB201308917D0 (en) | Delivery | |
| GB201319792D0 (en) | Formulations | |
| IL241109A0 (en) | Targeted vaccines for veterinary use | |
| HK1224228A1 (zh) | 新型製劑 | |
| HK1214951A1 (zh) | 眼用製劑 | |
| SG11201509194SA (en) | Radiomitigating pharmaceutical formulations | |
| HK1223559A1 (zh) | 用於促性腺激素的配方 | |
| HK1213273A1 (zh) | 重組因子 製劑 | |
| HK1214531A1 (zh) | 穩定的靜脈內製劑 | |
| IL253125A0 (en) | Preparations based on tetracaine for use as an anesthetic | |
| SI2815740T1 (sl) | Oftalmični sestavek | |
| GB2520410B (en) | Digital applanation tonometer | |
| GB201308035D0 (en) | Delivery | |
| GB201306262D0 (en) | Controlled delivery watering can |